Reflow Medical launches DEEPER CORONARY study in coronary in-stent restenosis

Reflow Medical, Inc. ignites a medical revolution with the first patient enrollments in a pilot study named “DEEPER CORONARY.” This pivotal research, set to radically change the treatment of coronary in-stent restenosis (ISR), a notorious villain in cardiovascular health, is now underway at three prestigious centers across New Zealand.

DEEPER CORONARY, officially known as the Drug-Eluting Coronary Spu StEnt as a Primary trEatment for in-stent Restenosis of the CORONARY arteries (NCT06117150), is not just a clinical trial; it’s a beacon of hope. ISR, often linked with a high risk of death and costly hospital re-admissions, has met its match with the Spur Elute system—a novel treatment that promises to revolutionize patient care by delivering potent sirolimus drugs directly to the affected areas without leaving any permanent implants.

At the heart of this innovation is the Spur Elute’s unique Retrievable Scaffold Therapy (RST), ingeniously designed to create channels that enhance drug uptake and expand the arterial lumen, all while ensuring nothing is left behind post-procedure. The first enrollment, witnessed by top interventional cardiologists Dr. William Lombardi and Dr. Kathleen E. Kearney from the UW Medicine Heart Institute, marks a critical step toward a new era of cardiovascular interventions.

Professor Scott Harding, M.D., the principal investigator and a renowned figure in the realm of complex coronary disease treatment, shares his excitement: “It’s exciting to take part in the study of this novel platform, which has the potential to successfully treat patients suffering from in-stent restenosis.” This sentiment is echoed by Reflow Medical’s CEO, Isa Rizk, who praises the team’s efforts and the collaborative role of Mobius Medical, the external CRO facilitating this landmark study.